ScripJohnson & Johnson is not ruling out being a late entrant into the obesity space. During an appearance at the Morgan Stanley Healthcare Conference on 4 September, CEO Joaquin Duato said the company is
ScripMerger-and-acquisition activity during the first quarter of 2024 was not likely to match the bustling pace of Q4 2023, when the aggregate dollar amount committed to acquisitions topped $52bn and nearl
In VivoWith the oft-cited patent cliff looming, big pharma companies are still looking to replenish pipelines. For many, partnering represents an important avenue to do so with its more limited financial ris
ScripEarly clinical trial results for Janux Therapeutics Inc. ’s JANX007 and JANX008 appear to validate the company’s Tumor Activated T-cell Engager (TRACTr) for the development of bispecific T-cell engag